Applied Therapeutics, Inc.

Report azionario NasdaqCM:APLT

Capitalizzazione di mercato: US$15.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Therapeutics Gestione

Criteri Gestione verificati 1/4

Applied Therapeutics Il CEO è Les Funtleyder, nominato in Nov2023, e ha un mandato di 2.25 anni. la retribuzione annua totale è $ 1.05M, composta da 50.4% di stipendio e 49.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.33% delle azioni della società, per un valore di $ 51.70K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 7.9 anni.

Informazioni chiave

Les Funtleyder

Amministratore delegato

US$1.1m

Compenso totale

Percentuale dello stipendio del CEO50.35%
Mandato del CEO2.3yrs
Proprietà del CEO0.3%
Durata media del management1.5yrs
Durata media del Consiglio di amministrazione7.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Jul 15

Here's Why Applied Therapeutics (NASDAQ:APLT) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Nov 15

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Applied...
Seeking Alpha • Sep 18

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review

Summary FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency. If the pre-NDA meeting of govorestat for SORD deficiency goes well, then the company would be in a good position to file an NDA for this drug in Q1 of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Applied Therapeutics: Pushing Towards FDA Approval

Summary Today, we revisit clinical stage developmental concern Applied Therapeutics, Inc. for the first time in 2024. The company is moving towards its first FDA approval before yearend, and could garner another approval for a different indication in 2025. An updated analysis around Applied Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Articolo di analisi • Aug 01

We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Applied...
Seeking Alpha • May 28

Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases

Summary Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors. Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion. AT-001’s efficacy in diabetic cardiomyopathy is inconclusive; significant results are only in certain subgroups. Hold APLT stock due to high risks despite potential in niche markets; it's suitable for a diversified high-risk portfolio segment. Read the full article on Seeking Alpha
Seeking Alpha • Feb 16

Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible

Summary Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if an NDA submission of govorestat for SORD deficiency could be done with only the positive 12-month interim data. 24-month interim results from the phase 3 INSPIRE study, using govorestat for the treatment of patients with SORD deficiency, is the next data readout to be expected. The NDA of govorestat for galactosemia has been submitted by the FDA and the EMA has validated the MAA; There is a good chance that Applied Therapeutics could receive regulatory approval for one or both of these territories. Read the full article on Seeking Alpha
Articolo di analisi • Feb 16

Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Applied Therapeutics...
Articolo di analisi • Nov 13

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Applied Therapeutics...
Articolo di analisi • Aug 11

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Articolo di analisi • May 19

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jan 19

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galactosemia in children. Investors and sell-side analysts are completely discounting the potential of the pipeline. Even in a conservative scenario, shares could reach $165 by 2028 or 38x upside potential. I provide various scenarios and my calculations on revenue potential, and enterprise value potential.
Articolo di analisi • Nov 11

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Articolo di analisi • Aug 13

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 15

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Feb 26

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Investors who take an interest in Applied Therapeutics, Inc. ( NASDAQ:APLT ) should definitely note that the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Les Funtleyder rispetto agli utili di Applied Therapeutics?
DataCompenso totaleStipendioUtili della società
Sep 30 2025n/an/a

-US$18m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$44m

Dec 31 2024US$1mUS$531k

-US$106m

Sep 30 2024n/an/a

-US$187m

Jun 30 2024n/an/a

-US$161m

Mar 31 2024n/an/a

-US$194m

Dec 31 2023US$675kn/a

-US$120m

Sep 30 2023n/an/a

-US$97m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$80kn/a

-US$83m

Sep 30 2022n/an/a

-US$95m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$229kn/a

-US$106m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$104m

Mar 31 2021n/an/a

-US$106m

Dec 31 2020US$303kn/a

-US$94m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$625kn/a

-US$46m

Compensazione vs Mercato: La retribuzione totale di Les ($USD 1.05M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 624.15K ).

Compensazione vs guadagni: La retribuzione di Les è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Les Funtleyder (55 yo)

2.3yrs
Mandato
US$1,053,846
Compensazione

Mr. Les D. Funtleyder has been an Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 2020. Mr. Funtleyder served as Interm CEO, CFO, Principal Financial Officer & Independent D...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Les Funtleyder
Interm CEO2.3yrsUS$1.05m0.33%
$ 51.7k
Corwin Hooks
Chief Commercial Officer1.8yrsUS$2.18m0.053%
$ 8.4k
Constantine Chinoporos
COO & Chief Business Officer2.2yrsNessun dato0.051%
$ 8.0k
Catherine Thorpe
Interim Chief Accounting Officer2.7yrsNessun datoNessun dato
Reena Colacot
Head of Quality1.1yrsNessun datoNessun dato
Todd Baumgartner
Chief Regulatory Officerless than a yearNessun datoNessun dato
Evan Bailey
Chief Medical Officerless than a yearNessun dato0.36%
$ 55.7k
Dottie Caplan
Executive Vice President of Patient Advocacy & Government Affairs.less than a yearNessun datoNessun dato
1.5yrs
Durata media
58.5yo
Età media

Gestione esperta: Il team dirigenziale di APLT non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Les Funtleyder
Interm CEO9.7yrsUS$1.05m0.33%
$ 51.7k
Jay Skyler
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Lawrence Steinman
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Teena Lerner
Lead Independent Director8.9yrsUS$265.00k0.069%
$ 10.8k
Stacy Kanter
Independent Director6.8yrsUS$267.50k0.035%
$ 5.5k
Gregg Stone
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Donald Landry
Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Donald D'Amico
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Roy Freeman
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Roxana Mehran
Member of Scientific Advisory Boardno dataNessun datoNessun dato
7.9yrs
Durata media
69yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di APLT sono considerati esperti (durata media dell'incarico 7.9 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/02/02 14:36
Prezzo dell'azione a fine giornata2026/02/02 00:00
Utili2025/09/30
Utili annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Applied Therapeutics, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Carter GouldBarclays
Paul ChoiGoldman Sachs
Luke DavisRBC Capital Markets